Related Experiment Video
Updated: Nov 6, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.4K
Diabetes: Pharmacotherapy for Type 2 Diabetes.
1University of Florida College of Pharmacy Department of Pharmacotherapy and Translational Research, 1225 Center Drive, Gainesville, FL 32610.
FP Essentials
|May 10, 2021
Summary
For type 2 diabetes management, metformin is the first-line drug. Additional therapies like SGLT2 inhibitors or GLP-1 receptor agonists are recommended for patients with cardiovascular or kidney disease.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes is a progressive condition characterized by hyperglycemia.
- Microvascular and macrovascular complications significantly increase morbidity and mortality.
- Current guidelines recommend individualized glycemic control targets.
Purpose of the Study:
- To outline current evidence-based treatment strategies for type 2 diabetes.
- To emphasize the importance of personalized treatment approaches.
- To highlight the role of pharmacologic interventions in managing diabetes pathophysiology.
Main Methods:
- Review of American Diabetes Association (ADA) guidelines.
- Analysis of pharmacologic options for type 2 diabetes management.
- Consideration of patient-specific factors and comorbidities.
Main Results:
- Metformin is the recommended first-line agent for type 2 diabetes.
- Sodium-dependent glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists are advised for high-risk patients.
- Multiple drug classes, including insulins and others, offer therapeutic options.
Conclusions:
- Comprehensive management of type 2 diabetes involves addressing multiple pathophysiologic mechanisms.
- Individualized A1c goals, typically below 7%, are crucial.
- Managing associated conditions like hypertension and hyperlipidemia is essential for preventing complications.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
663
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
663
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:36Carbohydrate Metabolism
12.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
12.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
398
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
398
01:22Diabetes Mellitus: Overview and Type I Subtype
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.1K
01:16Insulin: Dosing Regimen and Adverse Effects
358
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
358